Sponsored Content for Paul Hopper

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Radiopharm cancer fight in international spotlight Bulls N' Bears 27 Sep 2022

Radiopharm cancer fight in international spotlight

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

ASX-listed Radiopharm Theranostics will be showcasing the potential of one of its tumour-blasting products that targets the deadly pancreatic cancer at a key meeting of nuclear medicine experts in Spain next month. A lecture will be given at a session on new radiopharmaceutical trials and is a watershed moment in the partnership forged by Radiopharm and Germany-based nuclear medicine specialist TRIMT.

Radiopharm inks two new deals for cancer fight Bulls N' Bears 04 Aug 2022

Radiopharm inks two new deals for cancer fight

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

A nanobody with its origins in the camel family, that is now being used to fight cancer, is at the centre of two agreements inked by Melbourne-based company Radiopharm Theranostics. One deal is a collaboration agreement with US-based Lantheus – a US$5 billion NASDAQ-listed radiopharmaceutical company. The other is with UK company biotech NanoMab and gives Radiopharm important intellectual property rights in a cancer-fighting product.

Chimeric closes in on cancer fighting technology Bulls N' Bears 25 May 2022

Chimeric closes in on cancer fighting technology

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Successful trials of one of its cancer killing technologies has given Chimeric Therapeutics the confidence to lock in a clinical platform deal that targets blood cancers and solid tumours. The company plans to convert the option it had over the Clinically validated, Off the shelf, Robust, Enhanced Natural Killer, or “CORE-NK” technology into an exclusive licence to develop multiple next- generation products.

Where markets meet medicine; a biotech entrepreneur at the tip of the spear Bulls N' Bears 14 Feb 2022

Where markets meet medicine; a biotech entrepreneur at the tip of the spear

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

If billionaire “prospector” Mark Creasy has the Midas touch when it comes to divining lucrative mineral deposits, Paul Hopper just might be the man who wields the mythical rod of Asclepius - the Greek God of medicine - when it comes to the equally lucrative ASX-listed biotechnology space. By any measure Hopper has experienced success listing and developing biotech companies on the ASX – and the last year was a good one.

Radiopharm scores coup with rare isotope supply deal Bulls N' Bears 01 Feb 2022

Radiopharm scores coup with rare isotope supply deal

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Cancer fighting biotech, Radiopharm Theranostics has gained access to a rare medical isotope from a Bill Gates start-up to accelerate the development of its pipeline of cancer treatment therapies. The company says “actinium-225” is a radioactive isotype that can be attached to a targeting antibody that will then selectively target and destroy cancerous tissue.

Radiopharm takes ownership of cancer fighting nano-tools Bulls N' Bears 25 Jan 2022

Radiopharm takes ownership of cancer fighting nano-tools

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Cancer fighting biotech, Radiopharm Theranostics has taken full ownership of the intellectual property rights of three cancer-fighting nanobodies that target a range of solid tumors including breast cancer. Radiopharm had held the licence to use the assets in its studies, however following the purchase, it now has exclusive world-wide use of the technology that is used in the diagnosis and treatment in a range of cancers.

X